SCHEMBL15529632

SCHEMBL15529632

O=C(Nc1ccc(O[C@@H]2CCN(C(=O)c3ccccc3)C2)cc1)N1CC(c2cccnc2)C1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 18/20 0.71
ALDH1A1 P00352 1/20 0.55
HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15529273 1.00 NAMPT (0.71) NAMPTALDH1A1HTT
SCHEMBL15529690 0.91 NAMPT (0.57) NAMPT
SCHEMBL15529769 0.91 NAMPT (0.57) NAMPT
SCHEMBL15529268 0.89 NAMPT (0.61) NAMPT
SCHEMBL15529272 0.89 NAMPT (0.61) NAMPT
SCHEMBL15529506 0.89 NAMPT (0.57) NAMPT
SCHEMBL15528817 0.88 NAMPT (0.68) NAMPT
SCHEMBL15529253 0.88 NAMPT (0.68) NAMPT
SCHEMBL15529443 0.88 NAMPT (0.68) NAMPT
SCHEMBL15529605 0.87 NAMPT (0.70) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US claimed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP claimed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US claimed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO claimed
US-9758511-B2 NAMPT inhibitors ABBVIE INC. (US) 2017-09-12 US disclosed
US-20160168134-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-16 US disclosed
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP disclosed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US disclosed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168134-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT NAMPT 1/4885ALDH1A1 1573/4885HTT 1065/4885
US-20140336168-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT NAMPT 1/4885ALDH1A1 1573/4885HTT 1065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.